2.62 USD
+0.03 (+1.16%)
2.63 USD
+0.01 (+0.38%)
Taking everything into account, RPTX scores 3 out of 10 in our fundamental rating. RPTX was compared to 525 industry peers in the Biotechnology industry. While RPTX has a great health rating, there are worries on its profitability. RPTX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year RPTX has reported negative net income.
- In the past year RPTX has reported a negative cash flow from operations.
- RPTX had negative earnings in each of the past 5 years.
- In the past 5 years RPTX reported 4 times negative operating cash flow.
1.2 Ratios
- RPTX has a Return On Assets (-56.96%) which is comparable to the rest of the industry.
- RPTX's Return On Equity of -62.71% is fine compared to the rest of the industry. RPTX outperforms 60.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.96% | ||
| ROE | -62.71% | ||
| ROIC | N/A |
ROA(3y)-30.96%
ROA(5y)-27.37%
ROE(3y)-36.88%
ROE(5y)-33.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- RPTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- RPTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- RPTX has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, RPTX has more shares outstanding
- RPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -0.18, we must say that RPTX is in the distress zone and has some risk of bankruptcy.
- RPTX has a Altman-Z score of -0.18. This is comparable to the rest of the industry: RPTX outperforms 59.43% of its industry peers.
- There is no outstanding debt for RPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.18 |
ROIC/WACCN/A
WACC8.03%
2.3 Liquidity
- RPTX has a Current Ratio of 10.71. This indicates that RPTX is financially healthy and has no problem in meeting its short term obligations.
- RPTX has a better Current ratio (10.71) than 84.19% of its industry peers.
- RPTX has a Quick Ratio of 10.71. This indicates that RPTX is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of RPTX (10.71) is better than 84.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.71 | ||
| Quick Ratio | 10.71 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 15.00% over the past year.
- Looking at the last year, RPTX shows a very negative growth in Revenue. The Revenue has decreased by -82.16% in the last year.
- Measured over the past years, RPTX shows a very strong growth in Revenue. The Revenue has been growing by 91.62% on average per year.
EPS 1Y (TTM)15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.94%
Revenue 1Y (TTM)-82.16%
Revenue growth 3Y91.62%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 16.74% on average over the next years. This is quite good.
- Based on estimates for the next years, RPTX will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-7.61%
EPS Next 2Y27.58%
EPS Next 3Y19.21%
EPS Next 5Y16.74%
Revenue Next Year-99.47%
Revenue Next 2Y-65.57%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- RPTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year RPTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as RPTX's earnings are expected to grow with 19.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.58%
EPS Next 3Y19.21%
5. Dividend
5.1 Amount
- RPTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
REPARE THERAPEUTICS INC / RPTX FAQ
What is the ChartMill fundamental rating of REPARE THERAPEUTICS INC (RPTX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to RPTX.
Can you provide the valuation status for REPARE THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to REPARE THERAPEUTICS INC (RPTX). This can be considered as Overvalued.
What is the profitability of RPTX stock?
REPARE THERAPEUTICS INC (RPTX) has a profitability rating of 1 / 10.
What is the expected EPS growth for REPARE THERAPEUTICS INC (RPTX) stock?
The Earnings per Share (EPS) of REPARE THERAPEUTICS INC (RPTX) is expected to decline by -7.61% in the next year.